PrLUXTURNA® is a gene therapy designed to deliver a normal copy of the *RPE65* gene to the cells of the retina[1†‡]

THE FIRST AND ONLY GENE THERAPY INDICATED IN VISION LOSS DUE TO INHERITED RETINAL DYSTROPHY CAUSED BY CONFIRMED BIALLELIC *RPE65* MUTATIONS[1,2*]

LUXTURNA® (voretigene neparvovec) is indicated in the treatment of adult and pediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic *RPE65* mutations and who have sufficient viable retinal cells.[1]



LUXTURNA® is administered as a subretinal injection after vitrectomy in each eye.

* Comparative clinical significance is unknown.

† Clinical significance has not been established.

‡ **Patients will receive a single dose of 1.5x10[11] vg of LUXTURNA® in each eye, no fewer than 6 days apart.[1]**

LUXTURNA® pharmacodynamics



Injection of LUXTURNA® into the subretinal space results in transduction of some retinal pigment epithelial cells with a cDNA encoding normal human RPE65 protein, thus providing the potential to restore the visual cycle.[1]

RPE=retinal pigment epithelium

Adapted from LUXTURNA® Product Monograph.[1]

LUXTURNA® voretigene neparvovec for subretinal injection

Scan to watch a quick video about LUXTURNA®

Genetic testing is appropriate for most patients with presumed inherited retinal degeneration (IRD)[3]

IRDs comprise a wide range of genetically and phenotypically heterogeneous diseases that lead to progressive visual loss.[3]

Consider including genetic testing as part of the baseline assessment of your patients[3]

Patients will receive a single dose of LUXTURNA® in each eye, no fewer than 6 days apart.

LUXTURNA® is administered as a subretinal injection after vitrectomy.

Safety and efficacy in pediatric patients (<4 years of age) and geriatric patients (≥65 years of age) have not been established.

Consult the Product Monograph at www.novartis.ca/luxturnamonograph for important information about:

- Contraindications in hypersensitivity to LUXTURNA®, ocular or periocular infection, active intraocular inflammation
- Relevant warnings and precautions regarding administration by an experienced retinal surgeon, endophthalmitis, permanent decline in visual acuity, retinal abnormalities, increased intraocular pressure, expansion of intraocular air bubbles, cataract development and/or progression, avoidance during pregnancy, vector shedding, and blood, tissue, and organ donation for transplantation
- Adverse reactions, drug interactions, and dosing instructions

The Product Monograph is also available by calling 1-800-363-8883 or medinfo.canada@novartis.com.

References: 1. LUXTURNA® Product Monograph. Novartis Pharmaceuticals Canada Inc. April 20, 2022. **2.** Data on file. Attestation letter. Novartis. October 7, 2020. **3.** American Academy of Ophthalmology. Recommendations on Clinical Assessment of Patients with Inherited Retinal Degenerations – 2016. www.aao.org/clinical-statement/recommendations-on-clinical-assessment-of-patients. Accessed on April 14, 2021.

NOVARTIS

LUXTURNA®
voretigene neparvovec
for subretinal injection

Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd.
Dorval (Quebec) H9S 1A9
www.novartis.ca
Tel: 514-631-6775 Fax: 514-631-1867
Medical Information Tel: 1-800-363-8883
or medinfo.canada@novartis.com

July/2022 - 210547E

REVIEWED BY PAAB

MEMBER OF INNOVATIVE MEDICINES CANADA